ADVANCED SOLID TUMORS

This study tests a new drug called XNW34017 in 150 people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors. The study has two parts: first finding the right dose, then testing that dose in…

This study tests a new drug called SKB565 in 180 adults (ages 18-75) with advanced solid tumors that have not responded to standard treatments or are not eligible for them. The goal is to see if the drug is safe and can shrink tumors. The study has three parts: finding the right …

This early-stage study tests a combination of two drugs—peginterferon alfa-2b and an anti-PD-1 antibody—in about 60 people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goal is to find the safest dose and see if the combina…

This early-stage study tests a new drug called GS-2426 in people with advanced solid tumors that lack a gene called MTAP. The main goal is to check the drug's safety and find the best dose. About 174 adults whose cancer has not responded to standard treatments will take part.

This early-stage study tests a new drug, BPI-572270, in adults with advanced solid tumors (lung, colorectal, pancreatic) that have specific RAS gene mutations. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 120 participants who …

This study tests an experimental daily pill, FS-207, in people with advanced solid tumors that have a specific DNA feature called MSI-H. The goal is to see if the drug is safe, how the body processes it, and whether it can shrink or control the cancer. About 156 adults whose canc…

This study tests new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants must have tried standard treatments without success. The goal is to see if these experimental therapies are safe and shrink tumors. Doc…

This early-stage study tests a new drug called HF50 in about 45 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also watch for any signs that the drug shrinks tu…

This early-phase study tests a new treatment called KXV01 TCR Lentinvivo for people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the right dose. About 30 adults aged 18 to 70 will take part, and researchers …

This early-phase study tests whether adding donor natural killer (NK) cells to standard maintenance therapy can help control advanced solid tumors like lung and colorectal cancer. About 20 adults will receive NK cell infusions alongside their usual drugs. The main goals are to ch…

This early-stage trial tests a new cell therapy called GK01 in 10 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and how the body processes the therapy, while also looking at whether it can shrink tumors or slow …

This study tests a new drug called LCB02A for people with advanced solid tumors that have a specific marker (CLDN18.2) and haven't responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, finding the safe…

This early-phase study tests a new treatment called WTX-212C, made from specially engineered red blood cells, in 24 people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the best dose. Participants receive the…

This early-stage study tests a new drug called CS5007 in people with advanced solid tumors that have not responded to other treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to find a safe dose and see if the drug ca…

This early-stage study tests a new treatment called KXV01 TCR Lentinvivo in 30 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. The treatment uses a virus to deliver cancer-fighting genes in…

This early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors when used alone or with other cancer m…

This early-phase study tests two experimental drugs, IMM2510 and IMM01, given together to people with advanced solid tumors that have not responded to at least one prior treatment. The goal is to find a safe dose and see if the combination can shrink tumors or slow their growth. …

This study tests a new drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, or ovarian cancer. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants will join thi…

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This study tests a new drug (SYS6006) combined with an immunotherapy (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The first part finds the safest dose, and the second part checks if the combo shrinks tumors better than the …

This study offers continued treatment with the experimental drug RVU120 to adults with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from it in an earlier study. Participants must have received at least 5 cycles of…

This early-phase study is testing a new drug called SYS6051 in about 114 people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must be 18 or o…

This early-phase study tests an experimental cell therapy called GK01 in 15 adults with advanced solid tumors (like stomach or lung cancer) that have stopped responding to standard treatments. The main goals are to find the safest dose and check for side effects. Researchers will…

This study tests a new drug, SKB118, in about 332 adults aged 18-75 with advanced solid tumors that have not responded to standard treatments or are not eligible for them. The trial has three parts to find the best dose and see if the drug shrinks tumors. The main goals are safet…

This early-phase study tests a new daily pill, KQB368, in adults with advanced solid tumors (like lung, colon, or uterine cancer) that have a KRAS G12S or G12C mutation and no standard cure. The main goals are to find a safe dose and see if the drug can shrink tumors. About 48 pa…

This early-phase study tests a new drug called WSK-IM02 in 9 adults with advanced solid tumors that have spread and caused fluid buildup in the chest or belly. The drug is given directly into the fluid space to see if it is safe and can shrink tumors or control the fluid. Partici…

This study tests an injectable drug called ALK-N001 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can shrink tumors or stop them from growing, and to check its safety. About 190 adults will take part in this ea…

This early-stage study tests a new drug called CS08399 in adults with advanced solid tumors or lymphoma that have a specific gene deletion (MTAP). The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 186 people will take part.

This early-stage study tests a treatment that uses a patient's own immune cells to fight advanced solid tumors like lung, liver, colorectal, and breast cancers. Doctors take blood, grow special immune cells in a lab, and give them back to the patient to help their body attack the…